Chemistry: analytical and immunological testing – For preexisting immune complex or auto-immune disease
Reexamination Certificate
2011-07-19
2011-07-19
Stoica, Elly-Gerald (Department: 1647)
Chemistry: analytical and immunological testing
For preexisting immune complex or auto-immune disease
C530S350000, C424S130100, C424S140100
Reexamination Certificate
active
07981693
ABSTRACT:
The present invention relates to a method aiding in the assessment of rheumatoid arthritis. The method especially is used in assessing the absence or presence of rheumatoid arthritis in vitro. It can be best practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of anti-CCP and serum amyloid A and correlating the concentrations determined to the absence or presence of rheumatoid arthritis. To further improve the assessment of RA in a method of this invention the level of one or more additional marker may be determined together with anti-CCP and serum amyloid A and be correlated to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and serum amyloid A in the diagnosis of rheumatoid arthritis and it teaches a kit for performing the method of the invention.
REFERENCES:
patent: 1213586 (2002-06-01), None
patent: 1431310 (2004-06-01), None
patent: WO 98/08946 (1998-03-01), None
patent: WO 98/22503 (1998-05-01), None
patent: WO 99/28344 (1999-06-01), None
patent: WO 99/35167 (1999-07-01), None
patent: WO 01/46222 (2001-06-01), None
patent: WO 03/050542 (2003-06-01), None
Cunane G. Amyloid precursors and amyloidosis in inflammatoryarthritis. Curr. Opin. Rheumatol. 13, 67-73, 2001.
O'Hara et al. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res. 2, 142-144, 2000.
Xu et al. Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA. Clin. Chem. Lab. Med., 44, 59-63, 2006.
Schellekens et al. The Diagnostic Properties of Rheumatoid Arthritis Antibodies Recognizing a Cyclic Citrullinated Peptide. Arth. Rheumat. 43, 155-163, 2000.
Suzuki et al, High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis, Scand. J. Rheumatol., 32, 197-204, 2003.
Kumon et al. , Rheumatoid arthrithis exhibits reduced acute phase and enhanced constitutive serum amyloid A protein in synovial fluid relative to serum. A comparison with C-reactive protein. J. Rheumatol. 24, 14-19,1997 (abstract only).
Al-Dehaimi, A. et al., “Serum Galactosyl Hydroxylysine as a Biochemical Marker of Bone Resorption,” Clinical Chemistry 45:5, 676-681 (1999).
Arnett, F. et al., “The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis,” Arthritis and Rheumatism, vol. 31, No. 3 (Mar. 1988) 315-324.
Ballara, S. et al., “Raised Serum Vascular Endothelial Growth Factor Levels are Associated with Destructive Change in Inflammatory Arthritis,” Arthritis and Rheumatism, vol. 44, No. 9, Sep. 2001, 2055-2064.
Bartfield, H., “Distribution of Rheumatoid Factor Activity in Nonrheumatoid States,” Ann. NY Acad. Sci. 168(1969) 30-40.
Bas, S. et al., “Comparative Study of Different Enzyme Immunoassays for Measurement of IgM and IgA Rheumatoid Factors,” Ann Rheum Dis 2002; 61: 505-510.
Billinghurst, R. et al., “Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage,” J. Cllin. Invest. vol. 99, No. 7, Apr. 1997, 1534-1545.
Bonde, M. et al., “Immunoassay for Quantifying Type I Collagen Degradation Products in Urine Evaluated,” Clin. Chem. 40/11, 2022-2025 (1994).
Brenchley P. et al., “Angiogenesis in inflammatory joint disease: a target for therapeutic intervention,” Clin Exp Immunol 2000; 121:426-429.
Burmeister, G. et al., “A selective method for determining MRP8 and MRP14 homocomplexes and heterocomplexes by sandwich ELISA for the discrimination of active and non-active osteoarthritis from rheumatoid arthritis in sera and synovial fluids,” Inflammopharmacology, 1995; 3, 221-230.
Chabas, D. et al., “The Influence of the Proinflammatory Cytokine, Osteopontin, on Autoimmune Demyelinating Disease,” Science, vol. 294, Nov. 23, 2001, 1731-1735.
Chambers, R. et al., “Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity,” Annals of the Rheumatoid Arthritis Diseases: 1983, 42, 665-667.
Cunnane, G. et al., “Serum Amyloid A in the Assessment of Early Inflammatory Arthritis,” The Journal of Rheumatology 2000; 27:1, 58-63.
Foell, D. et al., “Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis,” Rehumatology 2003; 42:1383-1389.
Friedman, J., “Regularized Discriminant Analysis,” Journal of the American Statistical Association, Mar. 1989, vol. 84, No. 405, 165-175.
Gineyts, E. et al., “Urinary excretion of glucosyl-galactosyl pyradinoline: a specific biochemical marker of synovium degradation,” Rheumatology 2001: 40:315-323.
Gundberg, C., “Biology, Physiology, and Clinical Chemistry of Osteocalcin,” Journal of Clinical Ligand Assay, vol. 21, No. 2, Summer 1998, 128-138.
Hastie, T. et al., The Elements of Statistical Learning, Springer Series in Statistics (2001).
Hochberg, M. et al., “The American College of Rheumatology 1991 Revised Criteria for the Classification of Rheumatoid Arthritis,” Arthritis and Rheumatism, vol. 35, No. 5 (May 1992) 498-502.
Horneff, G. et al., “Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis,” Clin Exp Immunol 1993; 91:207-213.
Ishiguro, N. et al., “Relationships of Matrix Metalloproteinases and their Inhibitors to Cartilae Proteoglycan and Collagen Turnover and Inflammation as Revealed by Analyses of Synovial Fluids From Patients with Rheumatoid Arthritis,” Arthritis and Rheumatism, vol. 44, No. 11, Nov. 2001, 2503-2511.
Johansen, J. et al., “Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction,” Scand J Rheumatol 2001; 30:297-304.
Jorgensen, C. et al., “IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications,” Clinical and Experimental Rheumatology, 14: 301-304, 1996.
Kaufmann, J. et al., “Hydroxypyridinium collagen crosslinks in serum, urine, synovial fluid and synovial tissue in patients with rheumatoid arthritis compared with osteoarthritis,” Rheumatology 2003; 42:314-320.
Kellgren, J. et al., “Radiological Assessment of Osteo-Arthrosis,” Ann. Rheum. Dis. (1957) 16, 494-502.
Knott, L. et al., “Collagen Cross-Links in Mineralizing Tissues: A Review of Their Chemistry, Function, and Clinical Relevance,” Bone, vol. 22, No. 3, Mar. 1998, 181-187.
Lee, D. et al., “Clinical Utility of the Anti-CCP Assay in Patients with Rheumatic diseases,” Ann Rheum Dis 2003, 62: 870-874.
Lee, S. et al., “Vascular Endothelial Growth Factor Levels in the Serum and Synovial Fluid of Patients with Rheumatoid Arthritis,” Clinical Experimental Rheumatology 2001: 19; 321-324.
Lorenzo, P. et al., A Novel Cartilage Protein (CILP) Present in the Mid-zone of Human Articular Cartilage Increases with Age, The Journal of Biological Chemistry, vol. 273, No. 36, Sep. 4, 1998, 23463-23468.
Marcellitti, J. et al., “Assessment of serological markers associated with rheumatoid arthritis. Diagnostic autoaintibodies and conventional disease activity markers,” Clinical and Applied Immunology Reviews 4(2003) 109-123.
McLachlan, G., “Discriminant Analysis and Statistical Pattern Recognition,” Wiley Series in probability and mathematical statistics (1992).
Migita, K. et al., “Serum Amyloid A Protein Induces Production of Matrix Metalloprtoeinases by Human Synovial Fibroblasts,” Laboratory Investigation, May 1998, Vo. 78, No. 5, 535-539.
Moore, T. et al., “Rheumatoid Factors,” Clin Biochem, vol. 26, pp. 75-84, 1993.
Mozes, G. et al., “Serum Amyloid A: An Extremely Sensitive Marker for Intensity of Tissue Damage in Trauma Patients and Indicator of Acute Response in Various Diseases,&#
Grunert Veit Peter
Karl Johann
Wild Norbert
Zolg Werner
Roche Diagnostics Operations Inc.
Stoica Elly-Gerald
LandOfFree
Combined measurement of anti-CCP and serum amyloid A to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined measurement of anti-CCP and serum amyloid A to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined measurement of anti-CCP and serum amyloid A to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2650585